Hims & Hers: Q1 2026 raises revenue guidance but confirms margin reset
HIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
5Results1Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Hims & Hers (HIMS): the consumer-health platform has scale; the proof test is mix quality
Primary-source Coverage Bootstrap of Hims & Hers, covering revenue scale, subscriber growth, GLP-1 mix shift, international expansion, cash generation, and the proof gates needed before higher conviction.
OpenHIMS this week: Canada GLP-1 expansion meets a $402.5M convert test
Hims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenHIMS quietly added a retention weapon. Now the numbers have to prove it.
Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenHIMS closed Eucalyptus. The global-platform claim just got real.
Hims & Hers completed the Eucalyptus acquisition on June 2, 2026. The close upgrades the scale story, but the real proof still has to show up in international revenue mix, retention, margins, and cash flow.
Open